Filtered By:
Therapy: Statin Therapy

This page shows you your search results in order of date. This is page number 8.

Order by Relevance | Date

Total 179 results found since Jan 2013.

LRP6 mediated signal transduction pathway triggered by tissue plasminogen activator acts through lipid rafts in neuroblastoma cells.
Abstract LDL receptor-related proteins 6 (LRP6) is a type I transmembrane receptor (C-terminus in cytosol), which appears to be essential in numerous biological processes, since it is an essential co-receptor of Wnt ligands for canonical β-catenin dependent signal transduction. It was shown that tissue plasminogen activator (tPA), physically interacting with LRP6, induces protein phosphorylation, which may have large implication in the regulation of neural processes. In this investigation we analyzed whether LRP6 is associated with lipid rafts following tPA triggering in neuroblastoma cells and the role of raft i...
Source: Journal of Cell Communication and Signaling - February 14, 2020 Category: Molecular Biology Authors: Riitano G, Manganelli V, Capozzi A, Mattei V, Recalchi S, Martellucci S, Longo A, Misasi R, Garofalo T, Sorice M Tags: J Cell Commun Signal Source Type: research

Effect of atorvastatin on LOX-1 and eNOS expression in collateral vessels of hypercholesterolemic rats.
CONCLUSIONS: Both hypercholesterolemia and oxLDL can induce endothelial dysfunction and impair collateral vessel growth via the LOX-1/eNOS pathway in rats, and atorvastatin treatment can restore the LOX-1/eNOS pathway to promote the growth of the collateral vessels, suggesting the potential of atorvastatin as a therapeutic agent to promote repair of collateral vessel injuries in ischemic diseases. PMID: 31852645 [PubMed - in process]
Source: Journal of Southern Medical University - November 29, 2019 Category: Universities & Medical Training Authors: Yinjuan T, Jianjun W, Yinglu G, Weijun C, Weijun T, Mingying L Tags: Nan Fang Yi Ke Da Xue Xue Bao Source Type: research

Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9
AbstractHypercholesterolemia is a leading cause of cardiovascular disease and mortality in men and women throughout the USA and abroad. The development of statins (HMG-CoA reductase inhibitors) to lower plasma atherogenic cholesterol levels and improve cardiovascular outcomes represents one of the greatest contributions to clinical science in the twentieth century, although residual risk remains even among statin-treated patients. Our understanding of lipid metabolism took a giant leap forward in 2003 with the discovery of proprotein convertase subtilsin/kexin type  9 (PCSK9), a low abundance circulating protein with an o...
Source: BioDrugs - November 27, 2019 Category: Drugs & Pharmacology Source Type: research

Simvastatin preparations promote PDGF-BB secretion to repair LPS-induced endothelial injury through the PDGFR β/PI3K/Akt/IQGAP1 signalling pathway.
Simvastatin preparations promote PDGF-BB secretion to repair LPS-induced endothelial injury through the PDGFRβ/PI3K/Akt/IQGAP1 signalling pathway. J Cell Mol Med. 2019 Oct 01;: Authors: Zheng X, Zhang W, Wang Z Abstract Endothelial barrier dysfunction is a critical pathophysiological process of sepsis. Impaired endothelial cell migration is one of the main reasons for endothelial dysfunction. Statins may have a protective effect on endothelial barrier function. However, the effect and mechanism of statins on lipopolysaccharide (LPS)-induced endothelial barrier dysfunction remain unclear. Simvastatin ...
Source: J Cell Mol Med - September 30, 2019 Category: Molecular Biology Authors: Zheng X, Zhang W, Wang Z Tags: J Cell Mol Med Source Type: research

Combination simvastatin and metformin synergistically inhibits endometrial cancer cell growth.
CONCLUSIONS: MET+SIM treatment synergistically inhibits endometrial cancer cell viability. This may be mediated by apoptosis and mTOR pathway inhibition. Our results provide preclinical evidence that the combination of these well-tolerated drugs may warrant further clinical investigation for endometrial cancer treatment. PMID: 31178149 [PubMed - as supplied by publisher]
Source: Gynecologic Oncology - June 5, 2019 Category: Cancer & Oncology Authors: Kim JS, Turbov J, Rosales R, Thaete LG, Rodriguez GC Tags: Gynecol Oncol Source Type: research

Ability to Suppress TGF- β-Activated Myofibroblast Differentiation Distinguishes the Anti-pulmonary Fibrosis Efficacy of Two Danshen-Containing Chinese Herbal Medicine Prescriptions
Conclusion: This study suggests that a clinically efficacious cardiovascular Chinese herbal medicine (DLP) can be successfully repurposed to treat a lung disease in pulmonary fibrosis guided by TCM theory. Our comparative study between DLP and DHP demonstrated a critical requirement of suppressing both pro-inflammatory and pro-fibrotic pathways for the treatment of pulmonary fibrosis, supporting that a multi-component prescription capable of “removing both phlegm and blood stasis” will better achieve co-protection of heart and lung in PHD. Introduction Idiopathic pulmonary fibrosis (IPF) is a chronic ...
Source: Frontiers in Pharmacology - April 23, 2019 Category: Drugs & Pharmacology Source Type: research

Lovastatin attenuates angiotensin II induced cardiovascular fibrosis through the suppression of YAP/TAZ signaling.
Abstract Angiotensin II (ANG II) is associated with fibrosis in both clinical and basic studies. Thus, we aimed to explore a mechanism by which ANG II induces fibrosis. 5 μM of ANG II was used in the in vitro study. The mouse cardiovascular fibrosis model was established by infused with AngII (1000 ng/kg/min) for 7 days and cotreated with lovastatin (10 mg/kg daily) or vehicle control (DMSO in saline). We found that ANG II activated yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ), two transcription factors that were shown to induce fibrosis. Inhibition of ras homol...
Source: Biochemical and Biophysical Research communications - March 25, 2019 Category: Biochemistry Authors: Wu P, Liu Z, Zhao T, Xia F, Gong L, Zheng Z, Chen Z, Yang T, Duan Q Tags: Biochem Biophys Res Commun Source Type: research

Simvastatin Protects Dopaminergic Neurons Against MPP < sup > + < /sup > -Induced Oxidative Stress and Regulates the Endogenous Anti-Oxidant System Through ERK
Conclusion: Our results provide strong evidence that ERK1/2-mediated modulation of the anti-oxidant system after simvastatin treatment may partially explain the anti-oxidant activity in experimental parkinsonian models. These findings contribute to a better understanding of the critical roles of simvastatin via the ERK1/2-mediated modulation of the anti-oxidant system, which may be relevant for treating PD.Cell Physiol Biochem 2018;51:1957 –1968
Source: Cellular Physiology and Biochemistry - December 4, 2018 Category: Cytology Source Type: research

Effect of atorvastatin on cardiomyocyte hypertrophy through suppressing MURC induced by volume overload and cyclic stretch.
Abstract MURC (muscle-restricted coiled-coil protein) is a hypertrophy-related gene. Hypertrophy can be induced by mechanical stress. The purpose of this research was to investigate the hypothesis that MURC mediates hypertrophy in cardiomyocytes under mechanical stress. We used the in vivo model of an aortocaval shunt (AV shunt) in adult Wistar rats to induce myocardial hypertrophy. We also used the in vitro model of cyclic stretch in rat neonatal cardiomyocytes to clarify MURC expression and the molecular regulation mechanism. The flexible membrane culture plate seeding with cardiomyocytes Cardiomyocytes seeded o...
Source: J Cell Mol Med - December 3, 2018 Category: Molecular Biology Authors: Cheng WP, Lo HM, Wang BW, Chua SK, Shyu KG Tags: J Cell Mol Med Source Type: research

ASAP pH-Sensitive Nanocarrier-Mediated Codelivery of Simvastatin and Noggin siRNA for Synergistic Enhancement of Osteogenesis
ACS Applied Materials& InterfacesDOI: 10.1021/acsami.8b10521
Source: ACS Applied Materials and Interfaces - August 16, 2018 Category: Materials Science Authors: Jinsheng Huang, Chaowen Lin, Jintao Fang, Xiaoxia Li, Jin Wang, Shaohui Deng, Sheng Zhang, Wanhan Su, Xiaoreng Feng, Bin Chen, Du Cheng, Xintao Shuai Source Type: research

PCSK9 inhibitors and LDL reduction: pharmacology, clinical implications and future perspectives.
Authors: Fitzgerald G, Kiernan T Abstract INTRODUCTION: PCSK9 inhibitors are monoclonal antibodies to proprotein convertase-subtilisin/kexin type 9 which significantly reduce LDL cholesterol concentration in vivo by inhibiting degradation of the LDL receptor in hepatocytes. The introduction of PCSK9 inhibitors heralded a new era of intensive LDL-C reduction with LDL-C concentrations lowered below levels ever thought possible with conventional treatments such as statins. With their introduction considerations regarding cost, clinical outcomes and long-term safety are paramount. Areas covered: This review examines th...
Source: Expert Review of Cardiovascular Therapy - July 8, 2018 Category: Cardiology Tags: Expert Rev Cardiovasc Ther Source Type: research

Kruppel-like factor 4 (KLF-4) plays a crucial role in simvastatin (SVT)-induced differentiation of rabbit articular chondrocytes.
This study indicates that KLF-4 plays critical role in SVT-caused chondrocytes differentiation. PMID: 29775609 [PubMed - as supplied by publisher]
Source: Biochemical and Biophysical Research communications - May 15, 2018 Category: Biochemistry Authors: Yu SM, Kim SJ Tags: Biochem Biophys Res Commun Source Type: research

Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Pre-Specified Secondary End Points in ORION 1.
Conclusions -Inclisiran produces significant and prolonged reductions in atherogenic lipoproteins, suggesting that inhibiting synthesis of PCSK9 through siRNA may be a viable alternative to other approaches which target PCSK9. Clinical Trial Registration -URL: https://www.clinicaltrials.gov. Unique identifier: NCT02597127. PMID: 29735484 [PubMed - as supplied by publisher]
Source: Circulation - May 7, 2018 Category: Cardiology Authors: Ray KK, Stoekenbroek RM, Kallend D, Leiter LA, Landmesser U, Wright RS, Wijngaard P, Kastelein JJ Tags: Circulation Source Type: research

PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDL-Cholesterol.
Abstract Statins are currently the major therapeutic strategies to lower low-density lipoprotein cholesterol (LDL-C) levels. However, a number of hypercholesterolemia patients still have a residual cardiovascular disease (CVD) risk despite taking the maximum-tolerated dose of statins. Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to low-density lipoprotein receptor (LDLR), inducing its degradation in the lysosome and inhibiting LDLR recirculating to the cell membranes. The gain-of-function mutations in PCSK9 elevate the LDL-C levels in plasma. Therefore, PCSK9 inhibitors become novel therapeutic appr...
Source: Mini Reviews in Medicinal Chemistry - April 22, 2018 Category: Chemistry Authors: Liu ZP, Wang Y Tags: Mini Rev Med Chem Source Type: research

Identification of Estrogen-Related Receptor Alpha Agonists in the Tox21 Compound Library.
This study is the first comprehensive analysis in discovering potential endocrine disrupters which affect the ERRα signaling pathway. PMID: 29216352 [PubMed - as supplied by publisher]
Source: Endocrinology - December 4, 2017 Category: Endocrinology Authors: Lynch C, Zhao J, Huang R, Kanaya N, Bernal L, Hsieh JH, Auerbach SS, Witt KL, Merrick BA, Chen S, Teng CT, Xia M Tags: Endocrinology Source Type: research